Seasonal Allergic Rhinitis - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Seasonal Allergic Rhinitis - Pipeline Review, H2 2016’, provides an overview of the Seasonal Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seasonal Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Seasonal Allergic Rhinitis

The report reviews pipeline therapeutics for Seasonal Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Seasonal Allergic Rhinitis therapeutics and enlists all their major and minor projects

The report assesses Seasonal Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Seasonal Allergic Rhinitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Seasonal Allergic Rhinitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Seasonal Allergic Rhinitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergy Therapeutics Plc

Faes Farma, S.A.

Glenmark Pharmaceuticals Ltd.

Hisamitsu Pharmaceutical Co., Inc.

Merck & Co., Inc.

Pfizer Inc.

Shionogi & Co., Ltd.

VentiRx Pharmaceuticals, ...

Allergy Therapeutics Plc

Faes Farma, S.A.

Glenmark Pharmaceuticals Ltd.

Hisamitsu Pharmaceutical Co., Inc.

Merck & Co., Inc.

Pfizer Inc.

Shionogi & Co., Ltd.

VentiRx Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Seasonal Allergic ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Seasonal Allergic Rhinitis Overview 6

Therapeutics Development 7

Pipeline Products for Seasonal Allergic Rhinitis - Overview 7

Seasonal Allergic Rhinitis - Therapeutics under Development by Companies 8

Seasonal Allergic Rhinitis - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Seasonal Allergic Rhinitis - Products under Development by Companies 11

Seasonal Allergic Rhinitis - Companies Involved in Therapeutics Development 12

Allergy Therapeutics Plc 12

Faes Farma, S.A. 13

Glenmark Pharmaceuticals Ltd. 14

Hisamitsu Pharmaceutical Co., Inc. 15

Merck & Co., Inc. 16

Pfizer Inc. 17

Shionogi & Co., Ltd. 18

VentiRx Pharmaceuticals, Inc. 19

Seasonal Allergic Rhinitis - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

asapiprant - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

bilastine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

desloratadine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

emedastine difumarate - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

GSP-301 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PF-06444752 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

PF-06444753 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Pollinex Quattro Tree - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

VTX-1463 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Seasonal Allergic Rhinitis - Dormant Projects 43

Seasonal Allergic Rhinitis - Discontinued Products 45

Seasonal Allergic Rhinitis - Product Development Milestones 46

Featured News & Press Releases 46

May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis 46

Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN 46

Oct 11, 2013: FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8 ...

List of Tables

Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Seasonal Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016 12

Seasonal Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016 13

Seasonal Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 14

Seasonal Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 15

Seasonal Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016 16

Seasonal Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016 17

Seasonal Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016 18

Seasonal Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Seasonal Allergic Rhinitis - Dormant Projects, H2 2016 43

Seasonal Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016 44

Seasonal Allergic Rhinitis - Discontinued Products, H2 2016 45

List of Figures

List of Figures

Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8 ...

List of Figures

Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports